Literature DB >> 16360422

Maturation delay of germ cells in fetuses with trisomy 21 results in increased risk for the development of testicular germ cell tumors.

Martine Cools1, Friedemann Honecker, Hans Stoop, Joris D Veltman, Ronald R de Krijger, Ewout Steyerberg, Katja P Wolffenbuttel, Carsten Bokemeyer, Yun-Fai Chris Lau, Stenvert L S Drop, Leendert H J Looijenga.   

Abstract

Trisomy 21 is associated with an increased risk for the occurrence of germ cell tumors in males. The development of these tumors is thought to be related to events in fetal life. A delay in the maturation of germ cells is one of the mechanisms that have been proposed for the development of these tumors in high-risk groups such as intersex patients. To investigate whether a delay in germ cell development also occurs in trisomy 21, we examined the gonads of 30 fetuses, neonates, and infants with trisomy 21 (19 males and 11 females) for the expression of several immunohistochemical germ cell markers throughout pregnancy and compared them with a series of 46 age-matched controls. The results of our study reveal a significant delay in germ cell development in fetuses with trisomy 21, especially in males. Prolonged expression of octamer binding transcription factor 3/4, in combination with an increased expression of testis-specific protein, Y-encoded, might have pathogenetic relevance for the development of testicular germ cell tumors in this population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16360422     DOI: 10.1016/j.humpath.2005.09.021

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

1.  Consensus statement on management of intersex disorders.

Authors:  I A Hughes; C Houk; S F Ahmed; P A Lee
Journal:  Arch Dis Child       Date:  2006-04-19       Impact factor: 3.791

2.  Treatment experiences of testicular cancer in Hispanic patients with Down's syndrome at the National Cancer Institute of Mexico.

Authors:  Jose Luis Aguilar-Ponce; Silvia Vidal-Millán; Carlos Molina-Calzada; Fatima Chilaca-Rosas; Jorge Martínez-Cedillo; Juan Carlos Cruz-López
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.405

3.  Tumorigenesis in Down's syndrome: big lessons from a small chromosome.

Authors:  Dean Nižetić; Jürgen Groet
Journal:  Nat Rev Cancer       Date:  2012-09-21       Impact factor: 60.716

Review 4.  Laparoscopic approach for gonadectomy in pediatric patients with intersex disorders.

Authors:  Andres Calvo; Maria Escolino; Alessandro Settimi; Agnese Roberti; Maria Grazia Caprio; Ciro Esposito
Journal:  Transl Pediatr       Date:  2016-10

Review 5.  A practical guide for evaluating gonadal germ cell tumor predisposition in differences of sex development.

Authors:  Louise C Pyle; Katherine L Nathanson
Journal:  Am J Med Genet C Semin Med Genet       Date:  2017-05-25       Impact factor: 3.908

Review 6.  Disorders of sex development: update on the genetic background, terminology and risk for the development of germ cell tumors.

Authors:  Martine Cools; Leendert H J Looijenga; Katja P Wolffenbuttel; Sten L S Drop
Journal:  World J Pediatr       Date:  2009-07-09       Impact factor: 2.764

Review 7.  A mini-review of familial ovarian germ cell tumors: an additional manifestation of the familial testicular germ cell tumor syndrome.

Authors:  Claudia Giambartolomei; Christine M Mueller; Mark H Greene; Larissa A Korde
Journal:  Cancer Epidemiol       Date:  2009-05-30       Impact factor: 2.984

8.  Exploration of the treatment challenges in men with intellectual difficulties and testicular cancer as seen in Down syndrome: single centre experience.

Authors:  Shaista Hafeez; Mausam Singhera; Robert Huddart
Journal:  BMC Med       Date:  2015-06-26       Impact factor: 8.775

Review 9.  Cannabinoid Receptors Signaling in the Development, Epigenetics, and Tumours of Male Germ Cells.

Authors:  Marco Barchi; Elisa Innocenzi; Teresa Giannattasio; Susanna Dolci; Pellegrino Rossi; Paola Grimaldi
Journal:  Int J Mol Sci       Date:  2019-12-18       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.